6ER-011 Drug utilisation study of bevacizumab in a teaching referral paediatric hospital

BACKGROUND: Bevacizumab is a humanised monoclonal antibody against vascular endothelial growth factor authorised for adult cancer treatments. There are several case series and clinical trials on the use of bevacizumab in paediatric tumours at dose range of 5 to 15 mg/kg every 2 to 4 weeks. PURPOSE:...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Hosp Pharm
Egile Nagusiak: Celma, M Sánchez, Busquets, F Bossacoma, Genestar, JL Vinent, Suárez, J Arrojo, Flaqué, M Villaronga, Escoda, A Comes, López, V Santa-María, Alcón, P Montoliu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 2018
Gaiak:
Section 6: Education and research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535719/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.504
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak